Does the media prefer CBLL or IRTC?

In the previous week, CeriBell had 8 more articles in the media than iRhythm Technologies. MarketBeat recorded 11 mentions for CeriBell and 3 mentions for iRhythm Technologies. iRhythm Technologies' average media sentiment score of 1.68 beat CeriBell's score of 0.52 indicating that iRhythm Technologies is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CeriBell 4 Very Positive mention(s) 3 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive iRhythm Technologies 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Which has stronger valuation and earnings, CBLL or TMDX?

TransMedics Group has higher revenue and earnings than CeriBell. CeriBell is trading at a lower price-to-earnings ratio than TransMedics Group, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio CeriBell $101.96M 9.41 -$53.41M -$1.76 N/A TransMedics Group $605.49M 4.95 $190.29M $3.89 22.28

Does the media prefer CBLL or TMDX?

In the previous week, TransMedics Group had 3 more articles in the media than CeriBell. MarketBeat recorded 14 mentions for TransMedics Group and 11 mentions for CeriBell. TransMedics Group's average media sentiment score of 0.62 beat CeriBell's score of 0.52 indicating that TransMedics Group is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CeriBell 4 Very Positive mention(s) 3 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive TransMedics Group 3 Very Positive mention(s) 4 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings & valuation, CBLL or ATRC?

AtriCure has higher revenue and earnings than CeriBell. CeriBell is trading at a lower price-to-earnings ratio than AtriCure, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio CeriBell $101.96M 9.41 -$53.41M -$1.76 N/A AtriCure $534.53M 5.63 -$11.45M $0.21 281.52

Is CBLL or ATRC more profitable?

AtriCure has a net margin of 1.85% compared to CeriBell's net margin of -64.73%. AtriCure's return on equity of 2.34% beat CeriBell's return on equity. Company Net Margins Return on Equity Return on Assets CeriBell -64.73% -44.85% -35.69% AtriCure 1.85% 2.34% 1.77%

Does the media refer more to CBLL or ATRC?

In the previous week, CeriBell had 2 more articles in the media than AtriCure. MarketBeat recorded 11 mentions for CeriBell and 9 mentions for AtriCure. AtriCure's average media sentiment score of 0.83 beat CeriBell's score of 0.52 indicating that AtriCure is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CeriBell 4 Very Positive mention(s) 3 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive AtriCure 4 Very Positive mention(s) 3 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation and earnings, AXGN or CBLL?

AxoGen has higher revenue and earnings than CeriBell. AxoGen is trading at a lower price-to-earnings ratio than CeriBell, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio AxoGen $251.17M 9.69 -$15.70M -$0.68 N/A CeriBell $101.96M 9.41 -$53.41M -$1.76 N/A

Is AXGN or CBLL more profitable?

AxoGen has a net margin of -13.36% compared to CeriBell's net margin of -64.73%. AxoGen's return on equity of -8.90% beat CeriBell's return on equity. Company Net Margins Return on Equity Return on Assets AxoGen -13.36% -8.90% -6.47% CeriBell -64.73% -44.85% -35.69%

Does the media prefer AXGN or CBLL?

In the previous week, CeriBell had 5 more articles in the media than AxoGen. MarketBeat recorded 11 mentions for CeriBell and 6 mentions for AxoGen. CeriBell's average media sentiment score of 0.52 beat AxoGen's score of 0.39 indicating that CeriBell is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AxoGen 0 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral CeriBell 4 Very Positive mention(s) 3 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer INSP or CBLL?

In the previous week, CeriBell had 5 more articles in the media than Inspire Medical Systems. MarketBeat recorded 11 mentions for CeriBell and 6 mentions for Inspire Medical Systems. Inspire Medical Systems' average media sentiment score of 0.85 beat CeriBell's score of 0.52 indicating that Inspire Medical Systems is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Inspire Medical Systems 4 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive CeriBell 4 Very Positive mention(s) 3 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

CeriBell (CBLL) Competitors

$25.00 +0.50 (+2.04%)

Closing price 04:00 PM Eastern

Extended Trading

$25.00 0.00 (-0.02%)

As of 05:27 PM Eastern

Compare

CBLL vs. IRTC, TMDX, ATRC, AXGN, and INSP

Should you buy CeriBell stock or one of its competitors? CeriBell's main competitors and comparable companies include iRhythm Technologies (IRTC), TransMedics Group (TMDX), AtriCure (ATRC), AxoGen (AXGN), and Inspire Medical Systems (INSP). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does CeriBell compare to iRhythm Technologies?

CeriBell (NASDAQ:CBLL) and iRhythm Technologies (NASDAQ:IRTC) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, media sentiment, earnings, dividends, analyst recommendations, risk, valuation and institutional ownership.

CeriBell currently has a consensus target price of $24.40, suggesting a potential downside of 2.40%. iRhythm Technologies has a consensus target price of $179.93, suggesting a potential upside of 61.01%. Given iRhythm Technologies' stronger consensus rating and higher probable upside, analysts plainly believe iRhythm Technologies is more favorable than CeriBell.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CeriBell	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71
iRhythm Technologies	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	2 Strong Buy rating(s)	2.94

iRhythm Technologies has a net margin of -1.69% compared to CeriBell's net margin of -64.73%. iRhythm Technologies' return on equity of 10.11% beat CeriBell's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CeriBell	-64.73%	-44.85%	-35.69%
iRhythm Technologies	-1.69%	10.11%	1.53%

CeriBell has a beta of 0.95, suggesting that its stock price is 5% less volatile than the broader market. Comparatively, iRhythm Technologies has a beta of 1.31, suggesting that its stock price is 31% more volatile than the broader market.

In the previous week, CeriBell had 8 more articles in the media than iRhythm Technologies. MarketBeat recorded 11 mentions for CeriBell and 3 mentions for iRhythm Technologies. iRhythm Technologies' average media sentiment score of 1.68 beat CeriBell's score of 0.52 indicating that iRhythm Technologies is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CeriBell	4 Very Positive mention(s)	3 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
iRhythm Technologies	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

iRhythm Technologies has higher revenue and earnings than CeriBell. iRhythm Technologies is trading at a lower price-to-earnings ratio than CeriBell, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CeriBell	$101.96M	9.41	-$53.41M	-$1.76	N/A
iRhythm Technologies	$825.34M	4.46	-$44.55M	-$0.43	N/A

Summary

iRhythm Technologies beats CeriBell on 12 of the 15 factors compared between the two stocks.

How does CeriBell compare to TransMedics Group?

CeriBell (NASDAQ:CBLL) and TransMedics Group (NASDAQ:TMDX) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, analyst recommendations, risk, media sentiment, profitability, earnings, institutional ownership and dividends.

TransMedics Group has higher revenue and earnings than CeriBell. CeriBell is trading at a lower price-to-earnings ratio than TransMedics Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CeriBell	$101.96M	9.41	-$53.41M	-$1.76	N/A
TransMedics Group	$605.49M	4.95	$190.29M	$3.89	22.28

TransMedics Group has a net margin of 22.69% compared to CeriBell's net margin of -64.73%. TransMedics Group's return on equity of 15.88% beat CeriBell's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CeriBell	-64.73%	-44.85%	-35.69%
TransMedics Group	22.69%	15.88%	5.95%

99.7% of TransMedics Group shares are owned by institutional investors. 17.7% of CeriBell shares are owned by company insiders. Comparatively, 6.9% of TransMedics Group shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, TransMedics Group had 3 more articles in the media than CeriBell. MarketBeat recorded 14 mentions for TransMedics Group and 11 mentions for CeriBell. TransMedics Group's average media sentiment score of 0.62 beat CeriBell's score of 0.52 indicating that TransMedics Group is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CeriBell	4 Very Positive mention(s)	3 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
TransMedics Group	3 Very Positive mention(s)	4 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

CeriBell has a beta of 0.95, suggesting that its share price is 5% less volatile than the broader market. Comparatively, TransMedics Group has a beta of 1.9, suggesting that its share price is 90% more volatile than the broader market.

CeriBell presently has a consensus target price of $24.40, indicating a potential downside of 2.40%. TransMedics Group has a consensus target price of $121.10, indicating a potential upside of 39.74%. Given TransMedics Group's higher possible upside, analysts clearly believe TransMedics Group is more favorable than CeriBell.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CeriBell	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71
TransMedics Group	1 Sell rating(s)	6 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.33

Summary

TransMedics Group beats CeriBell on 13 of the 17 factors compared between the two stocks.

How does CeriBell compare to AtriCure?

CeriBell (NASDAQ:CBLL) and AtriCure (NASDAQ:ATRC) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, profitability, media sentiment, earnings, analyst recommendations and dividends.

99.1% of AtriCure shares are owned by institutional investors. 17.7% of CeriBell shares are owned by insiders. Comparatively, 4.0% of AtriCure shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

CeriBell currently has a consensus target price of $24.40, suggesting a potential downside of 2.40%. AtriCure has a consensus target price of $53.30, suggesting a potential downside of 9.84%. Given CeriBell's higher probable upside, research analysts clearly believe CeriBell is more favorable than AtriCure.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CeriBell	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71
AtriCure	0 Sell rating(s)	4 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.75

AtriCure has a net margin of 1.85% compared to CeriBell's net margin of -64.73%. AtriCure's return on equity of 2.34% beat CeriBell's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CeriBell	-64.73%	-44.85%	-35.69%
AtriCure	1.85%	2.34%	1.77%

In the previous week, CeriBell had 2 more articles in the media than AtriCure. MarketBeat recorded 11 mentions for CeriBell and 9 mentions for AtriCure. AtriCure's average media sentiment score of 0.83 beat CeriBell's score of 0.52 indicating that AtriCure is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CeriBell	4 Very Positive mention(s)	3 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
AtriCure	4 Very Positive mention(s)	3 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

CeriBell has a beta of 0.95, meaning that its stock price is 5% less volatile than the broader market. Comparatively, AtriCure has a beta of 1.26, meaning that its stock price is 26% more volatile than the broader market.

AtriCure has higher revenue and earnings than CeriBell. CeriBell is trading at a lower price-to-earnings ratio than AtriCure, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CeriBell	$101.96M	9.41	-$53.41M	-$1.76	N/A
AtriCure	$534.53M	5.63	-$11.45M	$0.21	281.52

Summary

AtriCure beats CeriBell on 12 of the 16 factors compared between the two stocks.

How does CeriBell compare to AxoGen?

AxoGen (NASDAQ:AXGN) and CeriBell (NASDAQ:CBLL) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their media sentiment, analyst recommendations, profitability, earnings, risk, institutional ownership, dividends and valuation.

In the previous week, CeriBell had 5 more articles in the media than AxoGen. MarketBeat recorded 11 mentions for CeriBell and 6 mentions for AxoGen. CeriBell's average media sentiment score of 0.52 beat AxoGen's score of 0.39 indicating that CeriBell is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AxoGen	0 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
CeriBell	4 Very Positive mention(s)	3 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

AxoGen has a beta of 1.16, suggesting that its share price is 16% more volatile than the broader market. Comparatively, CeriBell has a beta of 0.95, suggesting that its share price is 5% less volatile than the broader market.

AxoGen has a net margin of -13.36% compared to CeriBell's net margin of -64.73%. AxoGen's return on equity of -8.90% beat CeriBell's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AxoGen	-13.36%	-8.90%	-6.47%
CeriBell	-64.73%	-44.85%	-35.69%

AxoGen currently has a consensus price target of $51.56, indicating a potential upside of 13.86%. CeriBell has a consensus price target of $24.40, indicating a potential downside of 2.40%. Given AxoGen's stronger consensus rating and higher possible upside, research analysts clearly believe AxoGen is more favorable than CeriBell.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AxoGen	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75
CeriBell	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71

AxoGen has higher revenue and earnings than CeriBell. AxoGen is trading at a lower price-to-earnings ratio than CeriBell, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AxoGen	$251.17M	9.69	-$15.70M	-$0.68	N/A
CeriBell	$101.96M	9.41	-$53.41M	-$1.76	N/A

80.3% of AxoGen shares are held by institutional investors. 2.4% of AxoGen shares are held by insiders. Comparatively, 17.7% of CeriBell shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

AxoGen beats CeriBell on 12 of the 17 factors compared between the two stocks.

How does CeriBell compare to Inspire Medical Systems?

Inspire Medical Systems (NYSE:INSP) and CeriBell (NASDAQ:CBLL) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, risk, media sentiment, valuation, earnings, analyst recommendations, profitability and dividends.

Inspire Medical Systems has higher revenue and earnings than CeriBell. CeriBell is trading at a lower price-to-earnings ratio than Inspire Medical Systems, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inspire Medical Systems	$911.98M	2.31	$145.42M	$4.62	15.78
CeriBell	$101.96M	9.41	-$53.41M	-$1.76	N/A

Inspire Medical Systems has a beta of 0.7, suggesting that its share price is 30% less volatile than the broader market. Comparatively, CeriBell has a beta of 0.95, suggesting that its share price is 5% less volatile than the broader market.

In the previous week, CeriBell had 5 more articles in the media than Inspire Medical Systems. MarketBeat recorded 11 mentions for CeriBell and 6 mentions for Inspire Medical Systems. Inspire Medical Systems' average media sentiment score of 0.85 beat CeriBell's score of 0.52 indicating that Inspire Medical Systems is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Inspire Medical Systems	4 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
CeriBell	4 Very Positive mention(s)	3 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

94.9% of Inspire Medical Systems shares are owned by institutional investors. 2.2% of Inspire Medical Systems shares are owned by insiders. Comparatively, 17.7% of CeriBell shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Inspire Medical Systems has a net margin of 15.03% compared to CeriBell's net margin of -64.73%. Inspire Medical Systems' return on equity of 8.64% beat CeriBell's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Inspire Medical Systems	15.03%	8.64%	7.45%
CeriBell	-64.73%	-44.85%	-35.69%

Inspire Medical Systems currently has a consensus price target of $66.50, suggesting a potential downside of 8.76%. CeriBell has a consensus price target of $24.40, suggesting a potential downside of 2.40%. Given CeriBell's stronger consensus rating and higher possible upside, analysts clearly believe CeriBell is more favorable than Inspire Medical Systems.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inspire Medical Systems	3 Sell rating(s)	11 Hold rating(s)	3 Buy rating(s)	2 Strong Buy rating(s)	2.21
CeriBell	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71

Summary

Inspire Medical Systems beats CeriBell on 10 of the 17 factors compared between the two stocks.

Get CeriBell News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CBLL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CBLL vs. The Competition

Export

Metric	CeriBell	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$959.45M	$5.48B	$7.23B	$15.12B
Dividend Yield	N/A	1.79%	2.57%	12.31%
P/E Ratio	-14.20	25.20	274.13	25.56
Price / Sales	9.41	43.06	639.15	86.28
Price / Cash	N/A	32.69	76.40	50.90
Price / Book	5.97	5.76	10.51	6.31
Net Income	-$53.41M	$151.55M	$3.48B	$357.99M
7 Day Performance	6.70%	0.97%	0.33%	0.29%
1 Month Performance	2.46%	-2.86%	-0.21%	-3.13%
1 Year Performance	109.21%	24.86%	22.62%	6.88%

CeriBell Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CBLL CeriBell	1.7251 of 5 stars	$25.00 +2.0%	$24.40 -2.4%	+109.9%	$959.45M	$101.96M	N/A	300	Analyst Upgrade High Trading Volume
IRTC iRhythm Technologies	3.9289 of 5 stars	$112.00 -2.4%	$179.93 +60.7%	-35.9%	$3.69B	$747.14M	N/A	2,400	Positive News Analyst Forecast
TMDX TransMedics Group	4.4811 of 5 stars	$88.28 +2.8%	$124.18 +40.7%	-26.5%	$3.07B	$668.47M	22.87	898	Insider Trade
ATRC AtriCure	2.1082 of 5 stars	$56.54 +1.3%	$52.00 -8.0%	+58.9%	$2.88B	$569.62M	269.20	1,350	Analyst Forecast Insider Trade
AXGN AxoGen	2.2488 of 5 stars	$45.13 +3.1%	$51.56 +14.2%	+171.6%	$2.43B	$225.21M	N/A	622

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CBLL) was last updated on 9/17/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

CeriBell (CBLL) Competitors

CBLL vs. IRTC, TMDX, ATRC, AXGN, and INSP

How does CeriBell compare to iRhythm Technologies?

Summary

How does CeriBell compare to TransMedics Group?

Summary

How does CeriBell compare to AtriCure?

Summary

How does CeriBell compare to AxoGen?

Summary

How does CeriBell compare to Inspire Medical Systems?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CBLL vs. The Competition

CeriBell Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

CeriBell (CBLL) Competitors

CBLL vs. IRTC, TMDX, ATRC, AXGN, and INSP

How does CeriBell compare to iRhythm Technologies?

Do analysts rate CBLL or IRTC?

Is CBLL or IRTC more profitable?

Which has more risk & volatility, CBLL or IRTC?

Does the media prefer CBLL or IRTC?

Which has better earnings and valuation, CBLL or IRTC?

Summary

How does CeriBell compare to TransMedics Group?

Which has stronger valuation and earnings, CBLL or TMDX?

Is CBLL or TMDX more profitable?

Do institutionals & insiders believe in CBLL or TMDX?

Does the media prefer CBLL or TMDX?

Which has more risk and volatility, CBLL or TMDX?

Do analysts prefer CBLL or TMDX?

Summary

How does CeriBell compare to AtriCure?

Do insiders and institutionals hold more shares of CBLL or ATRC?

Do analysts rate CBLL or ATRC?

Is CBLL or ATRC more profitable?

Does the media refer more to CBLL or ATRC?

Which has more volatility and risk, CBLL or ATRC?

Which has preferable earnings & valuation, CBLL or ATRC?

Summary

How does CeriBell compare to AxoGen?

Does the media prefer AXGN or CBLL?

Which has more risk and volatility, AXGN or CBLL?

Is AXGN or CBLL more profitable?

Do analysts rate AXGN or CBLL?

Which has better valuation and earnings, AXGN or CBLL?

Do insiders & institutionals believe in AXGN or CBLL?

Summary

How does CeriBell compare to Inspire Medical Systems?

Which has preferable valuation and earnings, INSP or CBLL?

Which has more risk & volatility, INSP or CBLL?

Does the media prefer INSP or CBLL?

Do insiders and institutionals hold more shares of INSP or CBLL?

Is INSP or CBLL more profitable?

Do analysts rate INSP or CBLL?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CBLL vs. The Competition

CeriBell Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools